

**Notice of References Cited**

Application/Control No.

09/679,147

Applicant(s)/Patent Under  
Reexamination  
TODO ET AL.

Examiner

Anne M Beckerleg

Art Unit

1632

Page 1 of 2

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,310,045 B1	10-2001	Barber et.al.	514/44
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Verma et.al.; Gene therapy- promises, problems and prospects, 1997, Nature, vol. 389: 239-242.
	V	Miller et.al.; Targeted vectors for gene therapy, 1995, FASEB J. 9: 190-199.
	W	Marshall; Gene Therapy's Growing Pains, 1995, Science, Vol. 269: 1050-1055.
	X	Orkins et.al.; REPORT AND RECOMMENDATIONS OF THE PANEL TO ASSESS THE NIH INVESTMENT IN RESEARCH ON GENE THERAPY, 1995.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# **Notice of References Cited**

Application/Control No.

09/679,147

Applicant(s)/Patent Under  
Reexamination  
TODO ET AL.

Examiner

Anne M Beckerleg

Art Unit

1632

Page 2 of 2

## **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

## **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1): 53-69.
	V	Restifo et.al.; Molecular Mechanisms Used by Tumors to Escape Immune Recognition: Immunogenethrapy and the Cell Biology of Major Histocompatibility Complex Class I: 1993, Journal of Immunotherapy 14: 182-190.
	W	Sturmhoefel et.al.; Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant, 1999, Cancer Research59: 4964-4972.
	X	Hollenbaugh et.al.; The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form gp39 with B cell co-stimulatory activity, 1992, The EMBRO Journal, Vol. 11, No.12: 4313-4321.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.